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Various studies have suggested that the gut microbiome interacts with the host and may have a significant role 
in the aetiology of obesity and Type 2 Diabetes (T2D). It was hypothesised that bacterial communities in obesity 
and T2D differ from control and compromise normal interactions between host and microbiota. Obesity and 
T2D were developed in rats by feeding a high-fat diet or a high-fat diet plus a single low-dose streptozotocin 
administration, respectively. The microbiome profiles and their metabolic potentials were established by 
metagenomic 16S rRNA sequencing and bioinformatics. Taxonomy and predicted metabolism-related genes in 
obesity and T2D were markedly different from controls and indeed from each other. Diversity was reduced in 
T2D but not in Obese rats. Factors likely to compromise host intestinal, barrier integrity were found in Obese and 
T2D rats including predicted, decreased bacterial butyrate production. Capacity to increase energy extraction via 
ABC-transporters and carbohydrate metabolism were enhanced in Obese and T2D rats. T2D was characterized 
by increased proinflammatory molecules. While obesity and T2D show distinct differences, results suggest that in 
both conditions Bacteroides and Blautia species were increased indicating a possible mechanistic link.
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INTRODUCTION
The worldwide incidence of obesity and diabetes mellitus 
(DM) has significantly increased in recent years and efforts to 
address this silently-killing disease are urgently required. During 
the last decade, several studies have focused on the role of the 
gut microbiota in maintenance of gut health and wellbeing. It has 
been proposed that an altered microbial-community might result 
in greater levels of energy being harvested from food, particularly 
from a high fat diet, and several mechanisms facilitate metabolic 
disorders, particularly Type 2 Diabetes (T2D) [1, 2]. These 
changes include the production of short chain fatty acids (SCFAs) 
and lipopolysaccharide (LPS) which cause chronic low-grade-
inflammation [3]. Microbiome-profiling has been developed to 
determine the metagenomic structure of bacterial communities 
based on analysis of 16S rRNA sequences with software such 
as Quantitative Insights Into Microbial Ecology (QIIME) 
[4]. Recently, Phylogenetic Investigation of Communities by 
Reconstruction of Unobserved States (PICRUSt) has been 
developed to provide a view of metagenome function from 16S 
rRNA metagenomics or from full genomes [5].
Rat models have significantly contributed to the study of the 
function and role of microbiota in the gastrointestinal tract and its 
association with diseases such as metabolic disorder and obesity 
[6, 7], type 1 diabetes [8–10] and other complex diseases [11]. A 
model of T2D in rats has been introduced by Reed et al. [12] and 
subsequently refined by various investigators (reviewed in [13]). 
The rats are maintained on a high-fat diet to produce obesity, 
hyperinsulinaemia, glucose intolerance and insulin resistance. 
Subsequent administration of a low dose of streptozotocin results 
in a reduction of pancreatic β-cell function. We hypothesise 
that the gut microbiome varies with phenotype and the aim of 
the present study was to characterize the composition of gut 
microbiota using 16S rRNA sequencing in two rat models: 
a model of obesity, induced by feeding a high-fat diet; and a 
model of T2D induced by high fat diet and a single, low-dose 
injection of streptozotocin (STZ). The identification of bacteria 
that contribute to protection of host and those that cause harm 
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will potentially open the door to novel therapies for obesity and 
T2D and will provide clues to links between the two metabolic 
diseases.
MATERIALS AND METHODS
Animal maintenance and treatment
In-house-bred, male Wistar rats (age 10–12 weeks, 250–350 g, 
n=24) were maintained at room temperature (25°C) and 12/12-hr 
light-dark cycle and housed in standard cages (3 rats/cage). At 
the beginning of the procedure (week 1), the rats were divided 
randomly into four groups, with 6 animals in each group and 
treated for a period of 12 weeks as described below. After 12 
weeks, faecal pellets were collected from each group early in the 
morning (7:30 am) from animals housed individually over-night 
and immediately stored at −80°C.
Control group: (Normal Diet Vehicle). Rats were fed a normal 
diet (RM1, Rat and Mouse No. 1 Maintenance Diet; SDS, UK) 
containing crude fat of 2.7% by weight. Energy provision by 
component is: 13% calories from fat, 22% from protein and 65% 
from carbohydrate with Gross Energy 14.72 MJ/kg (Summary 
composition in Supplementary Table 1; full analysis at http://
www.sdsdiets.com/pdfs/RM1P-E-FG.pdf). They received a 
single intraperitoneal (I/P) injection of citrate buffer (pH 4.4) in 
a volume of 1 mL kg−1 at 4 weeks. Rats were maintained on the 
same diet for another 8 weeks.
STZ-alone group: (Normal Diet Streptozotocin). Rats were 
fed a normal RM1 diet and received a single I/P injection of 
streptozotocin (STZ) in citrate buffer at 30 mg kg−1 at 4 weeks, 
and maintained on same diet for another 8 weeks.
Obese group (Ob): (High-Fat Diet Vehicle). Rats were fed a 
high fat diet (HFD; product code 821424, SDS, UK) containing 
crude fat of 22% by weight. Energy provision by component 
is: 45% calories from fat, 18% from protein and 37% from 
carbohydrate with Gross Energy 19.67 MJ/kg (Supplementary 
Table 1). They also received a single I/P injection of citrate buffer 
(pH 4.4) in a dose of 1 mL kg−1 at 4 weeks. Rats were maintained 
on HFD for another 8 weeks.
Diabetic group (T2D): (High-Fat Diet STZ). Rats were fed 
a HFD and injected I/P with a single I/P injection of STZ at 
30 mg kg−1 at 4 weeks. Rats were maintained on HFD for another 
8 weeks.
Animal weights and blood glucose were measured weekly. 
Blood glucose levels were measured using a glucometer (Accu-
Check Aviva System; Roche Diagnosis, USA). An insulin 
tolerance test (ITT) was carried out in Control (Control; n=3) 
and Diabetic (T2D; n=3) groups 10 weeks after-the vehicle or 
STZ injection. Rats were fasted for 6 hr then received an I/P 
injection of bovine insulin (1U kg−1; Sigma, UK). Blood samples 
were collected from the tail tip just before insulin administration 
(time 0) and at 30, 60, and 120 min after glucose/insulin injection 
for measurement of blood glucose concentration using the 
glucometer.
Bacterial DNA extraction from faecal pellets and Illumina 
MiSeq sequencing
Genomic DNA was isolated, within one day of faecal collection 
using the QIAamp DNA Stool Mini Kit (QIAGEN Limited, 
Manchester (UK)) following the manufacturer’s protocol. 
Separate isolations were made from three individual pellets/
animal with material being taken from three separate locations 
on each pellet (180–220 mg for each animal), then placed in a 
2 mL Lysing Matrix E (4 mm glass beads) microcentrifuge tubes 
(MP Biochemicals, Strasbourg). Tube contents were thoroughly 
homogenized in ASL Buffer using a FastPrep®-24 Instrument 
(MP Biomedicals, UK) at 4.5 M second−1 for 30 seconds. A 
single DNA sample for each individual animal was recovered by 
pooling equal quantities of the separate DNA preparations and 
stored at −80°C prior to sequencing.
Purified DNA was used for PCR amplification and sequencing 
of 16S rRNA genes on an Illumina MiSeq instrument with 2 × 
300 base-pair paired-end reads at GATC Biotech (Germany). 
Universal primers of 16S rRNA genes were used to amplify the 
hypervariable regions, V3–V5 (V3F (357F), V5R (926R)). In a 
second PCR, Illumina TruSeq adapters and tag sequences were 
attached prior to sequencing. Reads have been submitted to the 
SRA with Accession Number SRP152214.
Bioinformatics and statistical analysis
Sequences were provided in a demultiplexed format and 
processed using Quantitative Insights Into Microbial Ecology 
(QIIME) v 1.8.0 [4]. Paired reads were merged (minimum 
overlap 18, tolerance 5) and quality filtered with default settings. 
Filtered sequences were clustered into Operational Taxonomic 
Units (OTUs) at 97% sequence similarity and Chimera sequences 
removed using USEARCH [14]. The most abundant sequences 
for each OTU were used as a representative to identify taxonomy 
by alignment with the GreenGenes database (gg_13_5, PyNAST 
default) [4, 15] prior to filtering with default settings. Alpha- and 
beta-diversity were calculated in QIIME using the OTU table.
Predicted molecular functions were generated from the 
taxonomy frequencies using PICRUSt [5] following the workflow 
described at https://github.com/LangilleLab/microbiome_helper/
wiki/PICRUSt-workflow. It is important to note that this 
approach produces only predictions of metabolic function. The 
OTU table produced by QIIME was converted to .biom format 
(http://biom-format.org/documentation/biom conversion.html) 
before a filtering step to remove those entries which do not have 
an identified organism. The filter-command produced a closed 
reference .biom table. Entries to this table were normalised to 
16S rRNA gene copy number to provide abundance numbers for 
each OTU. Kyoto Encyclopedia of Genes and Genomes (KEGG) 
orthologs (KOs) were then predicted prior to them being collapsed 
at level three to provide pathway predictions. The abundance 
data was normalized to the geometric mean [16] of values for 
‘house-keeping’ functions in genetic information processing 
[5]. To evaluate the significance of particular taxa to defined 
pathways (L3) within each group, the predicted contribution of 
taxa, identified by regression analysis as being connected to the 
pathway, were summed.
Relative abundance is presented as mean ± SEM and differences 
within and between groups were assessed using GraphPad Prism 
6 by: Dunn’s multiple comparison tests after one-way ANOVA; 
Bonferroni multiple comparison tests after two-way ANOVA for 
differences among more than two groups; Dunnett’s multiple 
comparison tests after two-way ANOVA to compare differences 
between the control group and other groups. A p value of <0.05 
was considered significant. Principal Coordinates Analysis 
(PCoA), heat map and hierarchical clustering analysis were 
conducted with the R software package version 3.2.1 (https://
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cran.r-project.org/bin/windows/base/old/3.2.1) to compare 
communities of two or more groups.
Compliance with ethical standards and ethical approval
All applicable international, national, and/or institutional 
guidelines for the care and use of animals were followed. Rats 
were treated with full approval of the Institute’s Animal Ethic’s 
and Welfare Committee; the procedures complied with UK 
Animal Scientific Procedures Act (1986) and were approved by 
the Home Office.
RESULTS
Induction of obesity and T2D in rats
Rats fed a high-fat diet and injected with vehicle exhibited a 
significant increase in body weight (p<0.05 vs. (versus) all other 
groups; Fig. 1a). Treatment with a high-fat diet and a low dose 
of STZ (T2D) induced a significant increase in blood glucose; 
significant hyperglycaemia was observed 1 week post-STZ 
injection in T2D rats (p<0.05 vs. all other groups) and this was 
maintained until the end of the study (Fig. 1b). The insulin 
tolerance test revealed that T2D rats were insensitive to insulin 
compared to control rats and displayed significant hyperglycaemia 
for the duration of the test (all p<0.05 vs. Controls; Fig. 1c).
Phylogenetic composition and the relative abundance of taxa of 
the microbiome communities
Basic statistics for the number of reads and clusters of similar 
sequences for all four groups are shown in Supplementary 
Table 2. Determination of the 16S rRNA sequences allowed 
phylogenetic classification via QIIME of OTUs of the gut 
microbiota from the level of phylum to family or genus. At 
phylum level (Supplementary Fig. 1) Bacteroidetes predominate 
over Firmicutes in the control group while similar levels for each 
were found in the STZ-alone animals. In contrast the proportion 
of each switch in the Obese and T2D groups and Firmicutes 
now predominate followed by Bacteroidetes. The proportion 
of Firmicutes was significantly higher (p<0.0001 and p<0.001) 
in T2D compared to both control and STZ-alone, while the 
abundance of Bacteroidetes was significantly lower (p<0.0001 and 
0.001). Firmicutes was enriched (p<0.0001) and Bacteroidetes 
lower (p<0.01) in Obese compared to STZ-alone while it was 
higher (p<0.05) in STZ-alone vs. control (Supplementary Fig. 1) 
and (p<0.01) in T2D vs. Obese.
At family level S24-7 family was the most abundant in both 
control and STZ-alone followed by various other families 
while in Obese, Ruminococcaceae was the predominant family 
and in T2D, Lachnospiraceae was the predominant family 
(Supplementary Fig. 2). When comparing bacteria at family 
levels, no significant differences were found between control 
and STZ-alone but differences were found for all other pairwise 
comparisons of the groups (Supplementary Fig. 3). For instance 
Bacteroidaceae and Lachnospiraceae were significantly enriched 
(p<0.0001) in the T2D vs. control and vs. STZ-alone, while the 
abundance of S24-7 decreased in both Obese and T2D vs. control 
and STZ-alone (p<0.0001). There were significant differences 
between nine families when Obese was compared to control and 
with STZ-alone while there were eight significant differences 
between Obese and T2D.
The abundant bacteria at genus level differ between the four 
experimental groups and are shown in Fig. 2 and Supplementary 
Table 3. In the control animals, the most abundant genera were 
Prevotella from Prevotellaceae family, while in the STZ-alone 
animals, the most abundant genera Prevotella and noticeably 
Allobaculum from Erysipelotrichaceae family. In the Obese 
group, Bacteroides from Bacteroidaceae family, [Prevotella] from 
[Paraprevotellaceae] family, Oscillospira and Ruminococcus 
from Ruminococcaceae family and Prevotella occur at highest 
levels. In T2D, the most abundant genera were Bacteroides, 
Prevotella and Blautia from Lachnospiraceae family. Figure 3 
shows the comparison of bacterial genera between the groups. 
Comparison of genera in control vs. STZ-alone showed no 
statistical difference but differences were apparent for all 
other groups. For instance a higher proportion of Blautia and 
Bacteroides were found in T2D vs. both control and STZ-alone 
while Allobaculum was higher in T2D vs. control (p<0.0001) 
(Fig. 3). Noticeably the ratio of Bacteroides/Prevotella was 
much higher in Obese and T2D than both control and STZ-alone 
(Supplementary Fig. 4).
Differences between genera in bacterial communities or 
groups were also apparent when data was analysed by PCoA and 
hierarchical clustering (not shown). The PCoA was conducted 
in a pairwise manner and is shown in Fig. 4 and reveals spatial 
separations between the groups. The exception was between 
Fig. 1. Total weight gain (g) from week 0 to week 12 (a), blood glucose (mmol/L) measured on week 12 (b) in Control, STZ-alone, Obese and 
Diabetic rats (n=6/group), and the insulin tolerance test compared Diabetic vs Control rats (c). Data are mean ± SEM. Significant difference from 
all other groups. *p<0.05, ***p<0.001.
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control and STZ-alone which could not be resolved and were 
overlapping or very close to each other (Fig. 4a). In contrast, 
Obese and T2D rats showed distinct differences when compared 
to the control group (Fig. 4b and c).
The differences in diversity of taxa across the groups were also 
shown by measures of both α- and β-diversity. Figure 5 illustrates 
α-diversity determined as PD-whole-tree, chao1 and observed-
species. Each of the measures showed a significant reduction 
in diversity in T2D compared to control. α-diversity in T2D 
was also significantly lower than in Obese rats. The distance-
difference of Unweighted and Weighted UniFrac β-diversity was 
measured for the bacterial community in the individual animals, 
pairwise, with animals within the same group and between 
groups (Supplementary Table 4). Supplementary Fig. 5 shows the 
separations of the distance matrix among the four groups with 
the exception of control vs STZ-alone and Obese vs. T2D of the 
weighted UniFrac distances by PCoA analysis.
The functional microbiome
The potential for bacterial metabolism in each bacterial 
group has been provided by PICRUSt. The normalised data 
was analysed by KEGG Category (level 2 e.g. Carbohydrate 
Fig. 2. Bacterial taxonomy and abundance of the gut metagenome at genus level between the four experimental groups.
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Fig. 3. Differences in abundance of genera between the four experimental groups.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Fig. 4. Comparison of bacterial communities at genus level in the four experimental groups based on Principal Coordinates Analysis (PCoA).
Comparisons are pairwise for individual rats in each group (n=6); Control: green, STZ-alone: red, Obese: blue and Diabetic: black.
K. Ibrahim, et al. 70
doi: 10.12938/bmfh.2019-031 ©2021 BMFH Press
metabolism) and Pathway (level 3 e.g. Butanoate metabolism), 
PCoA, heatmaps and hierarchical clustering and results are shown 
in Fig. 6 and Supplementary Fig. 6. So as to focus on major 
functional activities, analysis of these data was made at level 2 
and significant differences were found between the four groups 
in transcription, translation, amino acid metabolism, biosynthesis 
of other secondary metabolites, carbohydrate metabolism, 
energy metabolism, enzyme families, glycan biosynthesis and 
metabolism, metabolism of cofactors and vitamins, nucleotide 
metabolism and xenobiotic biodegradation and metabolism 
(Supplementary Fig. 6). PCoA showed spatial separation of all 
groups (Fig. 6a). Supplementary Fig. 6 shows the hierarchical 
clustering and heatmaps among the four experimental groups 
and these data show again a clear separation. Because of the 
role of in gut health, butyrate and propionate metabolism were 
analysed at level 3. Figure. 6b shows that butyrate production was 
significantly lower in T2D compared to other groups. The level 
of propionate was also determined by group and metabolism was 
significantly reduced in T2D vs. both control and Obese (Fig. 6b). 
Glycolysis/gluconeogenesis, metabolism of starch and sucrose 
and fructose and mannose and ABC transporters were significantly 
higher in Obese and T2D vs both control and STZ-alone groups 
and also T2D vs. Obese (Fig. 6c). Processes producing bacterial-
derived inflammatory molecules were also affected as shown in 
Fig. 6d. Bacterial biosynthesis of Lipopolysaccharide (LPS) and 
LPS biosynthesis proteins were higher in Obese and T2D, while 
peptidoglycan biosynthesis and bacterial toxins were higher in 
T2D compared to the other three groups.
Correlation coefficients have been calculated to analyse 
the relationship of SCFA metabolism and LPS biosynthesis to 
individual gut microbiota (Supplementary Fig. 7). It was found 
that Turicibacter genus and undefined genus of both S24-7 and 
Peptostreptococcaceae families were positively correlated to the 
butyrate production while genus of Blautia, and [Ruminococcus] 
and unclassified genus of Lachnospiraceae family were negatively 
associated with butyrate production. Both Ruminococcus 
and [Prevotella] (without STZ-alone) were positively linked 
to propionate metabolism. Also, Bacteroides was positively 
correlated with LPS biosynthesis. The relative abundances of 
bacteria that either produce butyric acid or propionic acid, are 
shown in Supplementary Fig. 7.
DISCUSSION
This study describes altered composition and metabolic 
potential of gut microbiota in rats fed with a diet containing 
high fat content that induced obesity or in combination with a 
single, low-dose STZ injection that induced T2D. Rats fed with 
HFD plus low-dose STZ developed insulin-insensitivity and 
hyperglycaemia consistent with the phenotype of T2D while 
STZ-alone caused no lasting physiological changes. Diabetic 
rats had weight loss as a result of loss of calories from sugar in 
the urine and the consequence of fat cell breakdown for energy 
production [9]. This is in contrast to Obese rats who exhibited a 
significant increase in body weight but with no change in blood 
glucose levels.
In this study the most abundant bacterial phyla were the 
Firmicutes and the Bacteroidetes (Supplementary Fig. 1) and 
there was a significant change in the relative abundance of these 
phyla in the diabetic animals. Similar changes have been observed 
in obesity in human [17].
PICRUSt metabolic analysis indicates potential bacterial-
derived metabolic capabilities and specifically on metabolism 
of SCFA, including butyrate or propionate and on inflammatory 
molecules that are increased in both the obese and diabetic 
condition. In this study predictions for levels of butyrate indicate 
that this metabolite would be decreased in both the Obese and 
T2D rats compared to those on the normal diet. At variance with 
this are the results from a meta-analysis of 8 data sets using 
PICRUSt to make predictions and found that these pathways 
Fig. 5. Bacterial α-diversity of bacterial communities in the four 
experimental groups.
Dunn’s multiple comparisons test was used to determine the relationship 
of α-diversity between the microbiome of the rat groups (n=6).*p<0.05, 
**p<0.01, ***p<0.001.
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would be increased [18]. It is likely that the conflict between our 
predictions and those of Jiao et al. [18] are a consequence of their 
use of a mixture of genera (5 mice, 3 rats) with variant species 
of each genus. It is generally accepted that butyrate production 
is beneficial and thus decreased production in Obese and T2D 
may be expected and those predictions could be tested in further 
experimentation. Butyrate is protective of the single cell-layer 
of epithelial cells along with its mucin coating while this barrier 
is compromised by inflammatory molecules [19]. In this study, 
the most abundant taxa in the control animals were unclassified 
genus of S24-7 family, Turicibacter genus and unclassified genus 
of Peptostreptococcaceae family (Fig. 2). PICRUSt positively 
linked these bacteria to butyrate production (Supplementary 
Fig. 7) and they have been identified as butyrate-producing 
bacteria (S24-7 family [20], Peptostreptococcaceae family [21], 
and Turicibacter genus [22]). Butyrate is produced as a bacterial 
metabolite and contributes to the integrity and thickness of 
the whole mucosal barrier [23] since it promotes the synthesis 
and secretion of mucin into the intestine [9, 24], stimulates 
Claudin-1, a protein of tight-junctions [25] and acts as an anti-
inflammatory [26]. Butyrate is also important in the activation 
of host GRP41/43 that elicits production of appetite-suppressing 
PYY and insulin-producing GLP1 [27]. In the STZ-alone rats, 
there was no significant difference in bacterial profile compared 
to control at the level of genus with the exception of an increase 
of Allobaculum genus (Figs. 2 and 3). A study of gut microbiota 
in mice [28] found that mice fed with low fat diet showed an 
enrichment of this genus. In fact, Allobaculum in the intestine 
encourages mucin release because this bacterium produces 
butyrate [29]. We found no difference in our predictions between 
Control and Obese groups for propionate metabolism again in 
contrast to the predictions of Jiao et al. [18] but consistent with 
the predictions of Lee and Ko [30] who found an improvement 
in metabolic parameters and increased propionate in metformin 
Fig. 6. Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analysis for predictions of the functional 
microbiome of each group.
PICRUSt was conducted at level 3. Principal Coordinates Analysis (PCoA) was used with individuals (a). The Mann Whitney test was used to estimate 
the significant differences; Metabolism of SCFA (butyrate and propionate) (b); energy related metabolism (glycolysis/ gluconeogenesis, starch and 
sucrose metabolism, fructose and mannose metabolism, and ABC transporters) (c) and processes producing bacterial-derived inflammatory molecules (d) 
Bacterial biosynthesis of lipopolysaccharide (LPS), LPS biosynthesis proteins, Bacterial toxins and Peptidoglycan biosynthesis.
*p<0.05, **p<0.01.
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administered mice on a high fat diet. Our results for predictions 
on butyrate and propionate are also in accord with a chemical 
study of human subjects and both of these SCFAs were decreased 
in faecal material from patients with T2D [31]. Additionally, a 
study employing genome-wide genotyping and gut metagenomic 
sequencing of a large panel of human subjects found a positive 
association between butyrate production and good insulin 
response to oral glucose administration [32].
The data from Obese rats highlighted the significant increase 
in Firmicutes phylum and associated decrease in Bacteroidetes. 
There was a significant enrichment of genus Bacteroides and a 
reduction of genus Prevotella in Obese rats compared to both 
control and STZ-alone groups. Bacteroides is a Gram-negative 
bacterium and is able to digest a variety of polysaccharides 
[33] producing fructose from fructans and then saccharolytic 
fermentation, produces acetate which is used for methanogenesis 
by Methanobrevibacter smithii [34]. Acetate is also utilised 
in energy metabolism by the host leading to increased adipose 
tissue. In the Obese rats, there was enrichment of [Prevotella]/ 
[Paraprevotellaceae] and this bacterium was predicted to be 
positively associated with propionate metabolism (Supplementary 
Fig. 7). Ruminococcus and Oscillibacter were increased in the 
Obese rats (Fig. 3). Some Ruminococcus sp. are acetate producers 
[35] and R. bromii and R. obeum were associated with obesity 
[36] and here a positive correlation between Ruminococcus and 
predicted propionate metabolism was found (Supplementary 
Fig. 7). There are three pathways of propionate metabolism 
and the association between Ruminococcus sp. and one of 
these has recently been confirmed in the human gut microbiota 
[37]. Reichardt and his colleagues found that the propanediol 
pathway occurs in some species of Ruminococcus genus and 
Lachnospiraceae family. Krych et al.[38], showed that the 
occurrence of bacteria such as Lachnospiraceae family, and both 
genera Oscillospira and Ruminococcus from Ruminococcaceae 
family are associated with the promotion of diabetes.
Perhaps the most dramatic changes in bacterial communities 
were found in the rats in which T2D had been induced. Further 
these changes appear to be associated with the physiological state 
expected of a diabetic animal. The diabetic rats had a decreased 
ratio of Firmicutes/ Bacteroidetes despite an increase of 
Bacteroides. The increase of Bacteroides was positively correlated 
with predicted LPS biosynthesis. Blautia was also increased and 
is a gram-positive, non-sporulating coccobacillus belonging to the 
Firmicutes phylum [39]. In humans Blautia was the predominant 
genus in pre-diabetic and T2D patients [40] and plays a vital role 
in the metabolism of glucose which it converts to acetate, lactate, 
hydrogen, ethanol and succinate in the gut [39]. A recent report 
by Ozato et al.[41], found that visceral fat in individuals in a 
Japanese population was inversely associated with Blautia. In our 
study Blautia was not significantly different in the Obese animals 
compared to the Control, however, our measure of Obesity was 
body weight rather than visceral fat. The predicted increase of 
bacterial gut-derived inflammatory molecules (for instance, LPS, 
flagellin and peptidoglycans) and predicted decreased butyrate 
production would be likely to be associated with the causation 
of inflammation and T2D [42]. Increased permeability of the 
gut membrane and low level inflammation caused by LPS and 
bacterial toxins has been reviewed [43].
As a working hypothesis we propose that the relationship 
between diet and the role of either beneficial or harmful gut 
microbiota in Wistar rats is that summarized in Fig. 7. The 
taxonomy of the bacterial communities and the bacterial 
metabolic capabilities were comparable in both control groups 
and predicted to promote the production of mucin and protection 
of the gut barrier layer. On the other hand, there were significant 
differences in the bacterial communities and metabolic potential in 
the Obese and T2D rats. Changes from a high ratio of Prevotella/ 
Bacteroides in controls to a low ratio in the T2D animals (data 
not shown) are associated with a healthy to diabetic transition and 
similar conclusions have been reached in humans and mice [44]. 
This is diet associated and these differences were observed when 
comparing both groups on a normal diet to both groups on a high 
fat diet. In humans Prevotella is associated with plant-based diets 
[45] and the normal diet provided for control rats is derived from 
a plant-based source including soya, wheat and barley (http://
www.sdsdiets.com/pdfs/RM1P-E-FG.pdf). However, single-
component diet change does not itself bring about a change 
in Prevotella/ Bacteroides ratio or a loss of body weight [46]. 
Intervention is clearly context specific and the development of 
therapies for metabolic diseases will need to be mindful of the 
antagonistic interaction between Prevotella and Bacteroides [47], 
dietary presence of complex carbohydrates or presence of a fat- 
and protein-rich diet.
Obesity predisposes to T2D but this is not the case in all 
instances of the disease [48, 49]. Identifying the pathway from 
obesity to T2D and the role of the gut microbiome is especially 
difficult because of the interaction of a large number of gut 
organisms, many of which have not been identified, with each 
other and the host and the balance between harmful and beneficial 
interactions [50]. Seeking links between obesity and T2D is not 
revealed by this study but some clues are provided. Blautia is 
present in Obese rats and significantly elevated in T2D rats. This 
is predicted to disrupt carbohydrate and glucose metabolism that 
reduces butyrate production with an increase of other SCFA and 
these products may contribute to energy capture by the host [51, 
52]. The one common feature of the microbial changes in both 
Obese and T2D rats is the increase of Bacteroides. Bacteroides 
are uniquely able to regulate the expression of genes for 
polysaccharide degradation and uptake and these are determined 
by the identity and availability of specific polysaccharides. They 
do this through different gene cassettes that are differentially 
controlled by intermediates of the breakdown process and may 
differ between species [53]. Thus we hypothesise that species 
within Blautia and Bacteroides are significantly associated with 
both Ob and T2D possibly as a mechanistic driver. The animal 
models share many characteristics that have been described from 
studies of humans either of obesity or T2D and future work may 
profit from a focus on Blautia and Bacteroides in these animal 
models and identifying which specific species in the two genera 
are altered.
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